Inflammation and NAD+ Decline
Chronic inflammation, often referred to as “inflammaging,” is a hallmark of aging. This persistent, low-grade inflammation contributes to the decline in NAD+ levels through multiple pathways.
Role of Inflammation in NAD+ Metabolism
Inflammation triggers the activation of immune cells, which express high levels of CD38. The increased activity of CD38 in these cells leads to accelerated NAD+ degradation. Moreover, inflammatory cytokines, such as TNF-α and IL-6, can upregulate the expression of CD38, further amplifying NAD+ consumption.
Inflammation also impacts the synthesis of NAD+. During chronic inflammatory states, the body’s ability to produce NAD+ through the de novo synthesis pathway is impaired. This pathway, which converts tryptophan into NAD+, is downregulated in the presence of inflammatory signals, leading to reduced NAD+ biosynthesis.
Mechanism of CD38-Induced NAD+ Decline
CD38 is an NAD+-consuming enzyme protein expressed on the surface of many immune cells, including macrophages and lymphocytes. With age, CD38 expression increases, leading to higher NAD+ consumption. This activity diminishes NAD+ availability, impairing functions that rely on this coenzyme, such as mitochondrial function, DNA repair, and cellular energy production.
CD38 also influences other NAD+-consuming enzymes, such as sirtuins and PARPs (poly ADP-ribose polymerases), further driving NAD+ depletion and promoting cellular aging.